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Abstract
Background: Routine assessment in (near) term pregnancy is often inaccurate for the identification of fetuses who are
mild to moderately compromised due to placental insufficiency and are at risk of adverse outcomes, especially when fetal
size is seemingly within normal range for gestational age. Although biometric measurements and cardiotocography are
frequently used, it is known that these techniques have low sensitivity and specificity. In clinical practice this diagnostic
uncertainty results in considerable ‘over treatment’ of women with healthy fetuses whilst truly compromised fetuses
remain unidentified. The CPR is the ratio of the umbilical artery pulsatility index over the middle cerebral artery pulsatility
index. A low CPR reflects fetal redistribution and is thought to be indicative of placental insufficiency independent of
actual fetal size, and a marker of adverse outcomes. Its utility as an indicator for delivery in women with reduced fetal
movements (RFM) is unknown. The aim of this study is to assess whether expedited delivery of women with RFM
identified as high risk on the basis of a low CPR improves neonatal outcomes. Secondary aims include childhood
outcomes, maternal obstetric outcomes, and the predictive value of biomarkers for adverse outcomes.
Methods: International multicentre cluster randomised trial of women with singleton pregnancies with RFM at term,
randomised to either an open or concealed arm. Only women with an estimated fetal weight≥ 10th centile, a fetus in
cephalic presentation and normal cardiotocograph are eligible and after informed consent the CPR will be measured.
Expedited delivery is recommended in women with a low CPR in the open arm. Women in the concealed arm will not
have their CPR results revealed and will receive routine clinical care. The intended sample size based on the primary
outcome is 2160 patients. The primary outcome is a composite of: stillbirth, neonatal mortality, Apgar score < 7 at 5min,
cord pH < 7.10, emergency delivery for fetal distress, and severe neonatal morbidity.
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Discussion: The CEPRA trial will identify whether the CPR is a good indicator for delivery in women with perceived
reduced fetal movements.
Trial registration: Dutch trial registry (NTR), trial NL7557. Registered 25 February 2019.
Keywords: Reduced fetal movements, Decreased fetal movements, Cerebroplacental ratio, CPR, Placental insufficiency,
Stillbirth, Fetal hypoxia, Neonatal morbidity
Background
Maternal perception of reduced fetal movements (RFM)
occurs in approximately 6 to 15% of pregnancies [1].
RFM often results from relatively benign causes such as
an altered fetal position or maternal distraction due to
other activities or stress. In some cases, however, it is an
important indicator pointing towards placental insuffi-
ciency. Placental insufficiency is usually a chronic
process of impaired exchange at the maternal-fetal inter-
face, leading to a deprived nutritional status of the fetus,
until acute hypoxia becomes life threatening. If long-
lasting and/or severe, fetuses typically become small for
gestational age. If the onset of placental insufficiency oc-
curs in late gestation, fetal size is more likely to be
within the normal range and the chronic placental dys-
function remains undetected. In these cases, RFM may
be the first sign of placental insufficiency and acute fetal
compromise [2].
RFM is associated with a 2.4–5-fold increase in still-
birth and other adverse outcomes such as asphyxia, neu-
rodevelopmental impairment in the offspring and
maternal hypertensive disease [3, 4]. Although the still-
birth rate (> 28 weeks gestation) in the Netherlands has
declined to 2.3 per 1000 in 2015, a large proportion of
stillbirths remains unexplained and in 20–30% of cases
substandard care is identified. Among these substandard
care factors, failure to respond to RFM is important.
There is still a large difference in stillbirth rates between
high-income countries, varying between 1.4 and 3.7 per
1000 pregnancies from 28 weeks gestational age onwards
[5]. Although these rates are declining, there is consider-
able variation between countries. This variation indicates
ample room for improvement.
Stillbirth prediction is difficult and the fear of vital
consequences leads to substantial overtreatment of
women reporting RFM. Functional parameters, such as
Doppler ultrasound and serum biomarkers, can help dis-
tinguish the compromised fetuses from healthy fetuses.
A low cerebroplacental ratio (CPR) on Doppler ultra-
sound reflects a decrease in resistance in the middle
cerebral artery (cerebral flow) and/or an increased resist-
ance in the umbilical artery (placental flow) indicating
redistribution of the fetal circulation: a compensatory
adaptation to nutrient and oxygen deprivation due to
placental insufficiency. A low CPR can identify a
compromised fetus regardless of fetal size [6–9], and
using the CPR combined with RFM may aid prediction
and consequently prevention of stillbirth [10].
The incidence of an abnormal CPR in RFM is approxi-
mately 6% [4]. There are no studies of a management
strategy based on an abnormal CPR for RFM. In a sys-
tematic review that included pregnancies of any risk pro-
file, the CPR outperformed the umbilical artery
pulsatility index in the prediction of emergency delivery
for fetal distress and prediction of composite adverse
outcome. A pooled sensitivity of 0.93 and specificity of
0.74 for perinatal death and a sensitivity of 0.59 and spe-
cificity of 0.91 for a composite adverse outcome was
found for a CPR <5th centile (equivalent to CPR < 1.1),
independent of birth weight [7, 11]. When analysing in-
dividual patient data from studies included in this sys-
tematic review, the CPR showed no added predictive
value for adverse perinatal outcome beyond the umbil-
ical artery pulsatility index, irrespective of gestational
age or fetal size [12]. A possible explanation for this con-
troversy could be that in the latter continuous data were
used whereas in the review a cut off value was applied to
determine (ab)normality.
It is unclear whether planned delivery for women pre-
senting with RFM based on CPR achieves better out-
comes than expectant management. Clinicians need to
balance the risks of prolonged placental insufficiency as-
sociated with a higher risk of adverse outcomes includ-
ing death against the risks of immediate delivery [9].
This uncertainty translates into considerable practice
variation regarding the use of CPR for management of
women reporting RFM [13]. Current guidelines in both
the Netherlands and the United Kingdom (UK) for the
management of RFM recommend ultrasound for fetal
biometry assessment and quantification of amniotic
fluid, as well as cardiotocography. Doppler measure-
ments are not recommended in these guidelines other
than in research setting [14, 15]. However, in 2017–2018
the CPR was already implemented in 22% of local proto-
cols in the Netherlands and this percentage has probably
increased since then [13].
The Lancet Stillbirth series identified the link between
RFM and stillbirth as key priority for research [16]. It
has been suggested to add other (bio) markers of placen-
tal dysfunction to biometry measurements in women
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reporting RFM [17]. Aside from the Doppler measure-
ments mentioned before, the pulsatility index of the
uterine artery is gaining attention as possible marker for
placental function. A high uterine artery pulsatility index
at term seems to be independently associated with an in-
creased risk of adverse perinatal outcome regardless of
fetal size [18]. Furthermore, maternal serum markers for
placental function, such as serum soluble fms-like tyro-
sine kinase-1 (sFlt-1) and placental growth factor (PlGF),
have considerable association with adverse outcomes
[19, 20]. None of these studies performed subgroup ana-
lyses for women reporting RFM. The effect of a societal-
awareness-intervention of women reporting RFM was
assessed in a large trial including over 400,000 pregnant
women. The intervention did not result in a significant
reduction of stillbirths, yet did increase iatrogenic (rela-
tive preterm) births, suggesting that the solution may
not be found in societal awareness but in a better risk
assessment at the individual level [21].
The aim of this cluster randomised trial is to compare
outcomes in women presenting with RFM at term, ran-
domised to either expectant management or immediate
induction of labour based on a low CPR for gestation.
We will compare neonatal and maternal outcomes, as
well as the healthcare costs in both groups. We will also




To assess whether expedited delivery (induction of deliv-
ery within 16 h) in pregnancies at term complicated with
RFM and an abnormal CPR (< 1.1) improves neonatal
outcome as compared to clinical management where the
CPR remains concealed.
Study design
We will conduct an international cluster randomised
controlled clinical trial with randomisation at hospital
level to either an open (CPR revealed) or concealed arm,
performed in the Netherlands, UK and Australia. The
protocol was drafted in accordance with the SPIRIT
(Standard Protocol Items: Recommendations for Inter-
ventional Trials) statements [22]. The trial was regis-
tered at the Dutch Trial Registry (NTR 7557) prior to
the start of inclusion, and is embedded within the Dutch
Society of Obstetrics and Gynaecology’s (Nederlandse
Vereniging van Obstetrie en Gynaecologie) NVOG clin-
ical trial consortium, a collaboration of gynaecology and
obstetric departments in the Netherlands.
Randomisation
Participating hospitals will be randomised to either con-
cealed or revealed CPR results for the duration of the
study. Hospitals will be randomised using a computer-
generated algorithm, stratified by country and number
of deliveries per year.
CPR concealment
Hospitals randomised to the concealed arm will not base
management on the CPR result. The CPR will be per-
formed by a sonographer or other physician who is not
involved in the participant’s treatment. The measure-
ments made will be printed during the scan and will not
be saved and thus not transferred to the data capture
software program. Only after delivery the scan results
can be completed in the data capture form. This ensures
that the CPR result, as well as the pulsatility indices of
the umbilical- and middle cerebral artery, are concealed
for the treating clinician until after delivery.
Participants and eligibility criteria
All women with a singleton pregnancy and perceived
RFM with a gestational age from 37+ 0 up to and includ-
ing 40+ 6 weeks, a fetus in cephalic presentation and nor-
mal cardiotocograph are eligible.
Exclusion criteria include:
 Small for gestational age, defined as abdominal
circumference < p10 based on the Verburg reference
curve [23] and/or estimated fetal weight < p10
according to Hadlock 3 formula [24] on ultrasound;
 Planned caesarean delivery, except an elective repeat
caesarean delivery;
 Abnormal (ultrasound) findings that indicate
immediate need for delivery*;
 Planned delivery within 4 days of presentation with
RFM;
 Major congenital malformations or chromosomal
abnormalities that can influence pregnancy
outcomes chosen for this study;
 Poorly controlled diabetes mellitus.
*This may for instance mean an absent or reversed
end diastolic flow in the umbilical artery, depending on
local protocol.
Outcome measures
Primary outcome is a composite of severe neonatal out-
come consisting of: stillbirth, neonatal mortality, Apgar
score < 7 at 5 min, pH < 7.10 (umbilical artery), emer-
gency delivery for fetal distress (need for cooling, caesar-
ean section or ventouse/forceps) and severe neonatal
morbidity (respiratory distress syndrome, hypoxic ische-
mic encephalopathy, sepsis, necrotizing enterocolitis and
supplementary oxygen therapy (> 4 days)).
Secondary outcomes include:
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 Mild and other neonatal outcomes, including
hypoglycaemia, hypothermia and admittance to
neonatal ward.
 Long-term child outcomes including general health,
development and behaviour. Child development and
behaviour will be assessed 24 months postpartum
using the validated Ages and Stages Questionnaire
(ASQ-3) and Child Behaviour Checklist (CBCL/1.5–5).
 Maternal outcomes including health related quality
of life, fear of childbirth, and development of
hypertensive disorders of pregnancy. Wellbeing and
fear and experience of childbirth are assessed using
the validated questionnaires European Quality of
Life 5-Dimension 5-Level (EQ-5D-5L), Wijma Delivery
Expectancy/Experience Questionnaire (WDEQ-A and
WDEQ-B) and posttraumatic stress disorder checklist
for DSM-5 (PCL-5).
 Analysis of maternal serum markers (PlGF, sFLt-1,
and PlGF/sFLt-1 ratio) in the context of normal and
abnormal CPR and in relation to (adverse) outcomes
and baseline characteristics.
 Analysis of the accuracy of routine placental
immunohistochemistry.
 Cost-effectiveness analysis of monitoring-
intervention strategy. A short-term and long-term
cost-effectiveness analysis from a societal perspective
will be performed as well as a budget impact
analysis.
Sample size calculation
We estimate a reduction of the incidence of the compos-
ite adverse neonatal outcome from 12 to 8%. The back-
ground risk of 12% is extrapolated from the existing
literature on RFM as applicable to our population [2, 21,
25–29]. This is an extrapolation because there has been
heterogeneity in reported outcome measures in RFM
studies. We anticipate an incidence of stillbirth and neo-
natal mortality (< 28 days) of 0.5%, and an incidence of
Apgar score < 7 at 5 min and/or pH < 7.10 umbilical ar-
tery and/or emergency delivery for fetal distress of 11%
(indicative for peripartum asphyxia). The less common
events are grouped into severe neonatal morbidity and
include: need for cooling, respiratory distress syndrome,
hypoxic ischemic encephalopathy, sepsis, necrotizing en-
terocolitis and, supplementary oxygen therapy (> 4 days).
For severe neonatal morbidity we anticipate an incidence
of 1% of which 0.5% overlaps with peripartum asphyxia.
Based on these assumptions, a total of 2160 patients
obtained from 24 clusters with 90 patients per cluster
(equal numbers of control and intervention), achieve
80.06% power to detect a difference in the primary out-
come from 12 to 8%, with an alpha of 5%, and an intra-
cluster correlation of 0.002.
Study setting
Eligible patients are recruited in the Netherlands, UK
and Australia. Approximately 24 hospitals will partici-
pate, consisting of both academic and large teaching
hospitals. Inclusion of a pilot centre in the Netherlands
started in June 2020 and overall recruitment in the
Netherlands started in January 2021. Recruitment in the
UK and Australia is planned to start in the second quar-
ter of 2021. A list of current study sites can be obtained
via the website [30].
Interventions
After recruitment and consent, an ultrasound scan for
fetal biometry, amniotic fluid volume, uterine artery pul-
satility index and CPR is performed. The pulsatility indi-
ces of both the umbilical artery and middle cerebral
artery will be reported aside from the calculated CPR.
Depending on the cluster, clinicians will be either
blinded or unblinded to the CPR. Expedited delivery is
pursued in women with an abnormal CPR – defined as
an CPR < 1.1 - in the open arm. In this case we aim to
start delivery within 16 h or an elective caesarean section
will be advanced. There are no criteria for discontinuing
the intervention other than participant request. In this
case she will be followed-up for intention-to-treat ana-
lysis. Women in the concealed arm will not have their
CPR results revealed and will receive routine clinical
care (Fig. 1).
A maternal blood sample will be taken from all partic-
ipants in the concealed arm and from participants with
an abnormal CPR in the open arm for serum biomarker
analyses and will be stored locally. Analyses are per-
formed in batch after study closure.
Additional studies
Depending on local guidelines and feasibility, the pla-
centa is submitted to the local pathology department for
routine examination conform the sampling procedures
laid out in the Amsterdam Placental Workshop Group
Consensus Statement [31]. We aim to analyse the results
of routine placental histology performed within routine
clinical care for suspected placental insufficiency. Tissue
blocks are stored locally and will be analysed centrally
for immunohistochemistry and methylation studies after
study closure.
Follow-up
Follow-up consists of online questionnaires at 6 weeks-,
12 months- and 24months postpartum (Fig. 1).
Insurance
According to national legal requirements an insurance is
taken out that covers injuries caused by participation of
this study. The insurance applies to injuries that become
Damhuis et al. BMC Pregnancy and Childbirth          (2021) 21:285 Page 4 of 8
apparent during the study period or within 4 years after
trial closure. Also a liability insurance in compliance
with national legal requirements is taken out.
Statistical analysis
Data analysis plan
The primary analysis will estimate the relative risk (RR)
with 95% confidence intervals and p-values for the com-
posite perinatal outcomes, using a generalized linear
mixed model with log link and binomial distribution,
with random intercepts and random slopes per cluster.
The primary analysis will be performed according to the
intention-to-treat principle. A per protocol analyses will
be done as secondary analysis.
Dichotomous secondary outcomes will be analysed
using the same method as the primary outcome.
Continuous data of secondary outcomes will be
assessed using a linear mixed model to estimate
mean differences, with random intercepts and slopes
as appropriate. Median differences will be calculated
as appropriate. A significance level of 5% will be
used for all tests. Interim testing for efficacy will not
be performed, hence the significance level does not
need to be lowered.
Given that all required data is collected for routine pa-
tient care in both primary and secondary care, missing
data is expected to be limited. Multiple imputation will
be used if required.
Fig. 1 Flow chart of the CEPRA study design and interventions. a Blood sample will not be drawn from participants with a normal CPR in the
open arm. ASQ: Ages and Stages Questionnaire, CBCL: Child Behaviour Checklist, CPR: cerebroplacental ratio, CTG: cardiotocograph, EQ-5D-5L:
European Quality of life 5-Dimension 5-Level, PCL-5: posttraumatic stress disorder checklist for DSM-5, SGA: small for gestational age, WDEQ:
Wijma Delivery Expectancy/Experience Questionnaire
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Data of quality of life measures will be obtained at four
time points and will be analysed using generalised esti-
mating equations.
For subgroup analyses we will assess the relationship
between pregnancy characteristics, outcomes and abnor-
mal serum biomarkers of PlGF and sFlt-1.
Economic evaluation
A cost-effectiveness analysis (CEA) will be performed
based on the empirical data we will obtain in the trial.
The CEA will be performed from both a healthcare- and
societal perspective. The primary outcome in the short-
term CEA will be the composite neonatal outcome. Costs
will include pregnancy monitoring, delivery according to
place of birth (hospital or at home), mode of delivery and
postnatal care. Additional analyses will be performed to
determine the effect of maternal biomarker-based risk se-
lection (normal or abnormal PlGF) on cost-effectiveness.
The long-term economic impact and CEA will be eval-
uated in a scenario analysis comparing costs of CPR
monitoring to costs of current routine monitoring, in-
cluding long-term costs caused by poor neonatal out-
come such as physical and intellectual disability. The
cost difference will be related to the difference in life-
years for the newborns to reflect the effect of avoided
stillbirth.
The budget impact analysis of management based on
CPR in women with RFM will be performed according
to the ISPOR guidelines from a societal perspective as
well from the health insurance and/or Dutch healthcare
budgeting framework perspective [32]. Also the incremen-
tal cost effectiveness ratio will be calculated by dividing
the difference in costs between expectant management
and the intervention by the difference in quality-adjusted
life years between usual care and intervention.
Ethics and disemmination
Patient consent
Eligible patients obtain verbal and written information
when the CTG appears normal. The information can be
read during the CTG recording and a short animation
video that has been developed to provide a study sum-
mary in laymen’s terms can be watched. If a patient
agrees to participate, written informed consent will be
obtained by an authorized person. Additional consent
will be obtained to store the residual material of the
maternal blood sample in a biobank for 50 years and to
be approached for follow-up- and future research.
Data collection and confidentiality
Data will be collected via Castor Electronic Data Cap-
ture, a web-based electronic case record form that meets
Good Clinical Practice (GCP) guidelines. All data will be
handled confidentially and access to the key of the
security code is strictly limited. After termination of the
study the research data will be preserved for 15 years in
keeping with the General Data Protection Regulation.
Participants may withdraw at any time for any reason
if they wish to do so. Unless they refuse to allow further
data collection, trial data will be collected for the
intention-to-treat analysis. If a participant refuses the
study intervention for any reason, follow-up (question-
naires) will be continued.
Data management procedures and data collection
forms can be found on the website [30].
Monitoring and safety
An independent data monitoring committee will moni-
tor data capture in compliance with GCP and other (in-
ter) national rules and regulations in order to achieve
high quality research and secure patient safety. Each par-
ticipating center will have a monitor visit at the start-
and end of the study and during the recruitment period.
Serious adverse events and any other significant prob-
lems will be reported to the ethics committee of the
University Medical Center of Groningen. An independ-
ent Data Safety Monitoring Board (DSMB) has been
established. The DSMB will review outcome data of the
first 600 and 1200 patients. An interim analysis for effi-
cacy will not be performed. The DSMB can recommend
early termination of the study in case of serious safety
concerns and a perceived negative benefit-risk balance.
These agreements have been documented in a DSMB
charter which can be found on the website [30].
Ethics
The trial will be conducted in compliance with the con-
temporary version of the Declaration of Helsinki, the
ICH GCP and other applicable regulations. Ethical ap-
proval was obtained from the ethical board of the Uni-
versity Medical Center of Groningen, the Netherlands
(METc 2019.488) and from Mater Misericordiae Ltd.
Human Research Ethics Committee, Australia (HREC/
MML/65382). The ethics approval from the UK is pend-
ing, with recruitment planned to begin once approval
has been granted.
Dissemination plan
Dispersion of the trial results will be accomplished by
publication in an international peer-reviewed scientific
journal and by presentations at (inter) national confer-
ences. When the results of the trial warrant changes in
the standard treatment guidelines of RFM, we anticipate
that the widespread execution of the trial in sites
throughout the Netherlands, the UK and Australia will
aid in its implementation.
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Discusson
The lack of diagnostic tools to correctly identify the fe-
tuses at risk for adverse outcomes and imminent still-
birth as a result of placental insufficiency within the
large group of pregnancies reporting RFM, is an every-
day problem for midwives and obstetricians. The CPR is
a promising functional marker to detect placental insuf-
ficiency and is increasingly implemented in clinical prac-
tice. Large practice variation in the use of Doppler
measurements for the indication of RFM exists among
both maternity hospitals and healthcare professionals.
The utility of the CPR on which to base clinical manage-
ment and time delivery in women with perceived RFM
has not been investigated. It is possible that expedited
delivery does not reduce the adverse neonatal outcomes.
Furthermore, other functional markers (including serum
biomarkers and the component pulsatility indices of the
umbilical artery, middle cerebral artery and uterine ar-
tery) have not been assessed for RFM and risk calcula-
tion. Evidence based guidelines on the use of Doppler
assessment for the indication of RFM are needed.
Strengths and challenges
A strength of this proposed study is the large control
group. The concealed arm (control group) is, however, a
logistic challenge. Several options to conceal the CPR re-
sult have been explored. Concealing the CPR result at
software- or ultrasound device level appeared to have
many organisational (many systems available for both
ultrasound machines and ultrasound data capture soft-
ware) and legal limitations. Despite considerable efforts
by ultrasound companies and ultrasound data capture
software builders, this blinding method proved to be un-
feasible. The current approach in which the CPR is con-
cealed for the treating physician was considered to be a
proper alternative and is extensively described in the
methods section.
Another strength is the sampling of serum biomarkers.
The predictive value of maternal biomarkers to detect
placental insufficiency at term is currently unknown. In
combination with the obtained Doppler results we hope
to facilitate the first steps in developing an individualised
prediction model to detect pregnancies at risk for pla-
cental insufficiency.
The cluster design was preferred over randomisation
at the individual patient level because it was expected
that both clinicians and the pregnant women would not
be willing to wait for spontaneous delivery once an ab-
normal CPR is measured. Randomisation at cluster level
was postulated to lead to a better implementation of the
intervention in participating sites.
This cluster RCT will determine whether the CPR is
an effective marker to guide management in pregnancies
at term complicated with RFM. If the CPR proves to be
an adequate indicator for delivery, expedited delivery will
be restricted to the smaller number of compromised fe-
tuses suffering from placental insufficiency, reducing
their stillbirth risk and improving long-term health.
Moreover, a larger group of women with perceived RFM
can be reassured and monitored less intensively, redu-
cing their burden of unnecessary intensified monitoring
and interventions, resulting in substantial lowering of
health costs.
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